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Zika virus (ZIKV) and dengue virus (DENV) are co-endemic in many parts of the world, but
the impact of ZIKV infection on subsequent DENV infection is not well understood. Here we
show in rhesus macaques that the time elapsed after ZIKV infection affects the immune
response to DENV infection. We show that previous ZIKV exposure increases the magnitude
of the antibody and T cell responses against DENV. The time interval between ZIKV and
subsequent DENV infection further affects the immune response. A mid-convalescent period
of 10 months after ZIKV infection results in higher and more durable antibody and T cell
responses to DENV infection than a short period of 2 months. In contrast, previous ZIKV
infection does not affect DENV viremia or pro-inflammatory status. Collectively, we find no
evidence of a detrimental effect of ZIKV immunity in a subsequent DENV infection. This
supports the implementation of ZIKV vaccines that could also boost immunity against future
DENV epidemics.
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Zika virus (ZIKV) is a re-emerging mosquito-borne Flavivirusthat has recently spread in the Americas1, and is associatedwith severe neurological sequelae2–4. ZIKV established itself
in tropical and sub-tropical regions that are endemic to other
closely related flaviviruses such as dengue virus (DENV). Both
viruses belong to the Flaviviridae family and are transmitted by
Aedes spp. mosquitoes. DENV is a global public health threat,
having two-thirds of world’s population at risk of infection, causing
~390 million infections annually5,6. DENV exists as four geneti-
cally similar but antigenically different serotypes (DENV1-4)7.
Exposure to one DENV serotype confers long-lived immunity
against a homotypic secondary infection. However, secondary
infection with a heterologous serotype of DENV is the major risk
factor to induce severe DENV disease8–10.
Due to the antigenic similarities between DENV and ZIKV,
concerns have been raised regarding the impact of DENV–ZIKV
cross-reactive immunity on the development of severe clinical
manifestations11,12. It has been demonstrated that DENV-
immune sera from humans can enhance ZIKV infection
in vitro13,14, and in vivo in immune-deficient mouse models15.
However, recent results from our group and others have shown
that previous flavivirus exposure—including DENV—may have
no detrimental impact on ZIKV infection in vivo in non-human
primates (NHP)16,17 and humans18. Moreover, these studies and
others suggest that previous DENV immunity may play a pro-
tective role during ZIKV infection involving humoral and cellular
responses19–23. On the other hand, little is known about the
opposite scenario, the role of a previous ZIKV exposure on
subsequent DENV infection, which is relevant to anticipate the
dynamics of forthcoming DENV epidemics.
The recent ZIKV epidemic in the Americas resulted in the
development of a herd immunity that may have an impact in
subsequent infections with other actively circulating flaviviruses
such as DENV. Thus, human subpopulations such as newborns,
international travelers from non-flavivirus endemic areas, or
DENV-naive subjects could be exposed to a ZIKV infection prior
to DENV—since DENV declined in the Americas during ZIKV
epidemic24. After the epidemic, herd immunity reduced ZIKV
transmission, and DENV will re-emerge and potentially infect
these DENV-naive ZIKV-immune subpopulations in the Amer-
icas or potentially in other geographic areas newly at risk25,26. An
epidemiological study based on active DENV surveillance in
Salvador, Brazil, suggests that the reduction of DENV cases after
the ZIKV epidemic is due to protection from cross-reactive
immune responses between these viruses27. Prospective experi-
mental studies are needed to confirm this hypothesis. NHPs
provide advantages such as an immune response comparable with
humans, and the normalization of age, sex, injection route, viral
inoculum, and timing of infection28. Although clinical manifes-
tations by flaviviral infections are limited in NHPs29, they have
been widely used as an advanced animal model for the study of
DENV and ZIKV immune response, pathogenesis, and vaccine
development16,17,28,30–33.
ZIKV antibodies (Abs) are capable of enhancing DENV
infection in vitro34. Characterization of the specificity of DENV
and ZIKV cross-reactive response revealed that ZIKV mono-
clonal Abs and maternally acquired ZIKV Abs can increase
DENV severity and viral burden in immune-deficient mouse
models35,36. George et al. showed that an early convalescence to
ZIKV induced a significant higher peak of DENV viremia and a
pro-inflammatory profile compared with ZIKV-naive status in
rhesus macaques37. A recent NHPs study showed that clinical and
laboratory parameters of ZIKV-immune animals were not asso-
ciated with an enhancement of DENV-2 infection. However, a
higher peak of DENV-2 plasma RNAemia in ZIKV-immune
animals was observed compared with DENV-2 serum RNAemia
loads in control animals, but the use of different sample types
may account for these differences38. Despite these findings, fur-
ther studies are needed to dissect the complementary role of the
innate, humoral, and cellular immune response to mechanistically
explain these findings. Particularly, there is no evidence of the
modulation and functionality of the T-cell response in the
ZIKV–DENV scenario. Available studies rely upon pathogenesis
and antibody studies, but there is no documented evidence as to
whether cell-mediated immunity (CMI)—specifically the func-
tional response of T cells—is modulated in a subsequent DENV
infection by the presence of ZIKV immune memory.
Shorter time interval between DENV infections result in a sub-
clinical secondary infection, while symptomatic secondary infec-
tions and severe DENV cases have been related with longer periods
between infections39–42. These findings suggest that high titers of
cross-reactive Abs play a time-dependent protective role between
heterotypic DENV infections. Despite this evidence from DENV
sequential infections, it remains poorly understood if the same
applies to the time interval between ZIKV–DENV sequential
infections. So currently, the role of multiple convalescent periods to
ZIKV in the outcome of DENV and other flavivirus infections is in
the forefront of discussions based on the limited studies available in
experimental models and a lack of characterized human prospective
cohorts of this scenario yet27,43–45.
The objective of our study is to investigate the immune mod-
ulatory role of an early convalescence and middle convalescence
after ZIKV infection on the outcome of a subsequent DENV
infection in rhesus macaques. We infect NHP cohorts who were
ZIKV immune for 10 months (middle convalescence), 2 months
(early convalescence) or naive for ZIKV with DENV. The
2 months cohort is selected for direct comparison with previous
work in NHP37, while the 10 months cohort is selected to test a
longer period of convalescence to ZIKV, where the cross-reactive
Abs are known to wane46. In each of these groups, we assess
DENV pathogenesis, the elicited Ab response, and characterize
the CMI. This study provides evidence that the presence
of ZIKV immune memory contributes to increase the magnitude
of the immune response—more efficient after longer ZIKV pre-
exposure—against a DENV infection, without promoting
enhancement of DENV viremia nor inducing higher levels of pro-
inflammatory cytokines.
Results
DENV challenge and clinical status of rhesus macaques. The
experimental design includes three cohorts of rhesus macaques
(Macaca mulatta), within the age range considered as young
adults (Supplementary Fig. 1k), that were challenged with DENV-
2 (NGC-44 strain), monitored, and bled for 3 months (Fig. 1).
Two cohorts were previously exposed to ZIKV: cohort 1
(ZIKVPF-10mo) was comprised of four animals that had been
exposed to ZIKV H/PF/2013 strain 10 months before DENV-2
challenge (mid convalescence), and cohort 2 (ZIKVPR-2mo)
comprised of six animals that had been exposed to ZIKV
PRVABC59 strain 2 months before DENV-2 challenge (early
convalescence). Both ZIKV strains used for previous exposure of
these groups are > 99.99% comparable in amino acid identity
(Supplementary Table 1). An additional cohort 3 (naive) included
four animals naive to ZIKV/DENV as a control group. After
DENV challenge, all macaques were extensively monitored, and
sample collection was performed at various timepoints up to
90 days post infection (dpi) for serum and PBMCs isolation.
Vital signs such as weight (kg) and temperature (°C) were
monitored. Also, complete blood cell counts (CBC) and
comprehensive metabolic panel (CMP) were performed before
(baseline: day 0) and after DENV infection at multiple timepoints
(CBC: 0, 7, 15 dpi; CMP: 0, 7, 15, 30 dpi). Neither symptomatic
manifestations nor significant differences in weight or tempera-
ture were observed in any of the animals after DENV infection up
to 90 dpi (Supplementary Fig. 1a, b). Likewise, no significant
differences between groups were detected in CBC parameters:
white blood cells (WBC), lymphocytes (LYM), neutrophils
(NEU), monocytes (MON), and platelets (PLT) after DENV
infection compared with basal levels of each group (Supplemen-
tary Fig. 1c–g). CMP levels showed no differences in alkaline
phosphatase and aspartate transaminase (AST) (Supplementary
Fig. 1h–i). Although within the normal range, levels of alanine
transaminase (ALT) were significantly higher in the ZIKVPR-
2mo group compared with its baseline at 7 dpi (p= 0.0379, two-
way ANOVA Dunnett test), but at 15 and 30 dpi values returned
to baseline levels (Supplementary Fig. 1j). Overall, except for the
isolated increase of ALT at 7 dpi in ZIKVPR-2mo, the clinical
profile suggests that the presence of ZIKV-immunity did not
significantly influence the clinical outcome of DENV infection.
DENV RNAemia not enhanced by previous ZIKV immunity.
RNAemia levels in NHPs serum were quantified by qRT-PCR at
baseline, 1–10, and 15 dpi to determine if the presence of early
convalescence (ZIKVPR-2mo) or mid convalescence (ZIKVPF-
10mo) to ZIKV alters DENV RNAemia kinetics. No significant
differences between groups were observed in detected levels of
DENV genome copies per milliliter of serum overtime (Fig. 2a).
We noted that in the ZIKVPF-10mo group, three out of four
animals were able to keep the RNAemia level below 103 genome
copies the next day after DENV infection. This group started an
early clearance of the RNAemia at 7 dpi, with only one out of four
animals having detectable levels by days 8 and 9 pi. For ZIKVPR-
2mo and naive animals, the clearance of detectable RNAemia
started at 8 dpi, in four out of six and one out of four of the
animals, respectively. Naive animals had the most delayed
clearance of RNAemia with at least half of the animals with
detectable levels of viral RNA until day 9 pi. RNAemia was
completely resolved in all animals by 10 dpi. In summary,
ZIKVPF-10mo had 7.25, ZIKVPR-2mo 7.5, and naive animals 8
mean days of detectable RNAemia after DENV infection
(Fig. 2b). In addition, the area under the curve (AUC) was cal-
culated, but no statistically significance differences were observed
in the RNAemia peak among groups (Supplementary Fig. 2).
However, the AUC trend to be lower in both ZIKV-immune
groups. In terms of the kinetics, a delay in the peak RNAemia set
point was observed in both ZIKV-immune groups (switch from
day 2 to days 5 and 6) followed by higher, but non-significant,
levels compared with the naive group, and a subsequent early
RNAemia clearance in both ZIKV-immune groups. Together
these results show that, although no statistically significant dif-
ferences among groups were observed, previous immunity to
ZIKV is not associated with an increase in DENV RNAemia; even
more, a mid-convalescence to ZIKV tended to develop a shorter
viremic period.
Pro-inflammatory cytokines not exacerbated by ZIKV immu-
nity. To determine if the characterized cytokine profile of an
acute DENV infection was modulated by ZIKV immunity, we
assessed the serum concentration (pg/ml) of eight cytokines/
chemokines by Luminex multiplex at baseline, 1, 2, 3, 5, 10, 15,
and 30 dpi. The naive group showed significant higher levels of
Type I interferon alpha (IFN-α) and pro-inflammatory cytokines
such as Interleukin-6 (IL-6), and monokine induced by IFN-
gamma (MIG/CXCL9) (Fig. 3a–c). IFN-α was highest at 5 dpi
(Fig. 3a: p < 0.0001 vs ZIKVPF-10mo and p= 0.0003 vs ZIKVPR-
2mo, two-way ANOVA Tukey test). IFN-α has been demon-
strated to be involved in the innate antiviral immunity, and
elevated levels are associated with higher viral load and antigen
availability. IL-6, a multifunctional cytokine involved in immune
response regulation and many inflammatory reactions showed
the highest levels at 1 dpi in naive animals (Fig. 3b: p= 0.0115 vs
ZIKVPF-10mo and p= 0.0185 vs ZIKVPR-2mo, two-way
ANOVA Tukey test). Finally, MIG/CXCL9, which is a potent
chemoattractant involved in leukocyte trafficking demonstrated
the highest levels at 10 dpi in naive animals (Fig. 3c: p= 0.0004 vs
ZIKVPR-2mo, two-way ANOVA Tukey test). On the other hand,
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Fig. 1 Experimental design for DENV-2 challenge of ZIKV-immune and naive macaques. Fourteen young adult male rhesus macaques (Macaca mulatta),
matched in age and weight, were divided into three cohorts. ZIKVPF-10mo (n= 4): composed of four animals (5K6, CB52, 2K2, and 6N1) that were
inoculated with 1 × 106 pfu/500 µl of the ZIKV H/PF/2013 strain subcutaneously 10 months before (middle convalescence) DENV-2 challenge. ZIKVPR-
2mo (n= 6): composed of six animals (MA067, MA068, BZ34, MA141, MA143, and MA085) that were inoculated with 1 × 106 pfu/500 µl of the
contemporary ZIKV PRVABC59 strain 2 months before (early convalescence) DENV-2 challenge. Both ZIKV strains used for previous exposure of these
groups are > 99.99% comparable in amino acid identity (Supplementary Table 1). Naive (n= 4): composed of four ZIKV/DENV naive animals (MA123,
MA023, MA029, and MA062) as a control group. Prior to DENV-2 challenge, all animals were subjected to quarantine period. All cohorts challenged
subcutaneously (deltoid area) with 5 × 105 pfu/500 µl of DENV-2 New Guinea 44 strain (NGC44). After DENV-2 challenge, all animals were extensively
monitored for evidence of disease and clinical status by vital signs, such as external temperature (°C), weight (Kg), CBC, and CMP panels at the Caribbean
Primate Research Center (CPRC). Blood samples were collected at baseline, 1–10, 15, 30, 60, and 90 days after DENV infection. In all timepoints, the blood
samples were used for serum separation (yellow). PBMCs isolation (red) was performed in different tubes with citrate as anticoagulant at baseline, 1, 2, 3,
7, 10, 15, 30, 60, and 90 days after DENV infection
of CXCL10 (IP-10) (Fig. 3g) at day 1 (p= 0.0198 vs ZIKVPR-
2mo, two-way ANOVA Tukey test), 5 (p= 0.0487 vs naive, two-
way ANOVA Tukey test), and 10 pi (p= 0.0009 vs ZIKVPR-2mo,
two-way ANOVA Tukey test). CXCL10 is a T-cell activating
chemokine and chemoattractant for many other immune cells.
Also, this group showed higher levels of perforin (Fig. 3h) at day
10 (p= 0.0024 vs naive and p= 0.0190 vs ZIKVPR-2mo, two-way
ANOVA Tukey test) and 15 pi (p= 0.0178 vs naive, two-way
ANOVA Tukey test). Perforin is an effector cytolytic protein
released by activated cytotoxic CD8+ T cells and natural killer
(NK) cells. No significant differences between groups were
observed for other pro-inflammatory citokines, such as monocyte
chemoattractant protein 1 (MCP-1), macrophage inflammatory
protein 1-beta (MIP-1β), and IL-1 receptor antagonist (IL-1RA)
(Fig. 3d–f). Collectively, these results demonstrate that the pre-
sence of ZIKV immunity does not exacerbate pro-inflammatory
status after DENV infection while mid-convalescence immunity
to ZIKV stimulated levels of mediators mainly involved in the
activation of cell-mediated immune response.
DENV and ZIKV cross-reactive antibody response. An ELISA-
based serological profile was performed to determine the con-
tribution of ZIKV immunity in the cross-reactive Ab response
before and after DENV infection. We assessed the levels of DENV
IgM and IgG, and cross-reactivity with ZIKV (IgM, IgG, NS1-
IgG, and EDIII–IgG) at multiple timepoints (Supplementary
Fig. 3). Naive cohort showed a significant higher peak of IgM
(Supplementary Fig. 3a) characteristic of a primary DENV
infection at 15 and 30 dpi (p < 0.0001 vs ZIKVPF-10mo and p=
0.0004 vs ZIKVPR-2mo, p= 0.0044 vs ZIKVPF-10mo and p=
0.0179 vs ZIKVPR-2mo, respectively, two-way ANOVA Tukey
test). This indicates the productive and acute DENV infection,
while ZIKV immune groups showed lower levels of IgM resem-
bling a heterotypic secondary infection. The total DENV IgG
levels (Supplementary Fig. 3b) of both ZIKV-immune groups
were significantly higher compared with naive since baseline
(cross-reactive ZIKV–IgG Abs) and 7, 15, 30, 60, and 90 (the
latter for ZIKVPF-10mo only) (ZIKVPF-10mo vs naive: p=
0.0010, p < 0.0001, p < 0.0001, p < 0.0001, p < 0.0001, p= 0.0016;
ZIKVPF-2mo vs naive: p= 0.0029, p= 0.0002, p < 0.0001, p <
0.0001, p= 0.0006; two-way ANOVA Tukey test). The ZIKVPF-
10mo group showed significant higher levels than ZIKVPR-2mo
group at 30 and 90 dpi (p= 0.0242 and p= 0.0348, two-way
ANOVA Tukey test). Overall, ZIKVPF-10mo developed higher
and long-lasting levels of DENV IgG.
In contrast, ZIKV IgM levels were under or near the limit of
detection in all groups over time after DENV infection, despite
several significant differences between groups (Supplementary
Fig. 3c). ZIKV IgG levels (Supplementary Fig. 3d) were high in
both ZIKV-immune groups at baseline and 7 dpi compared with
naive (p < 0.0001 vs naive, two-way ANOVA Tukey test),
suggesting that although different pre-infecting ZIKV strains, the
previous elicited IgG response against both ZIKV strains is
comparable. After DENV infection, an increase of ZIKV IgG was
shown and remain constantly high at 15, 30, 60, and 90 dpi in both
ZIKV-immune groups (p < 0.0001 vs naive for all timepoints, two-
way ANOVA Tukey test), suggesting that DENV has the potential
to stimulate ZIKV-binding Ab-producing plasmablasts. In addition,
to elucidate the composition of similar ZIKV IgG levels in ZIKV-
immune groups, we measured ZIKV-specific NS1 IgG (Supple-
mentary Fig. 3e) and ZIKV-specific EDIII IgG (Supplementary
Fig. 3f) levels. Although ZIKVPR-2mo showed significant differ-
ences compared with naive at 30, 60, and 90 dpi (p < 0.0001, p=
0.0001, p= 0.0159; two-way ANOVA Tukey test), we observed a
significantly higher expansion and long-lasting response of ZIKV
NS1-specific Abs in the ZIKVPF-10mo group compared with the
ZIKVPR-2mo group at baseline, 60 and 90 dpi (p= 0.0036, p=
0.0071, p= 0.0294; two-way ANOVA Tukey test) and also
compared with naive animals at all timepoints (p < 0.0001, two-
way ANOVA Tukey test). Moreover, higher magnitude of ZIKV-
specific EDIII–IgG levels in the ZIKVPF-10mo group than in the
ZIKVPR-2mo group was observed compared to naïve at baseline
(ZIKVPF-10mo only), 15, 30, and 60 (ZIKVPF-10mo vs naive: p=
0.0092, p < 0.0001, p < 0.0001, p= 0.0034; ZIKVPR-2mo vs naive:
p= 0.0003, p= 0.0014, p= 0.0055; two-way ANOVA Tukey test),
suggesting that a ZIKV mid-convalescence promotes an expansion
of higher magnitude of ZIKV EDIII–IgG Abs from ZIKV memory
B cells (MBC). However, those higher cross-reacting levels decrease
overtime as expected. In summary, a boost of DENV and ZIKV Abs
is triggered by the presence of ZIKV immunity, and the expansion
of specific- and cross-reactive Abs is higher on magnitude and
durability when a mid-convalescence immunity to ZIKV is present.
DENV neutralization is boosted by ZIKV immunity. Neu-
tralizing antibodies (NAbs) are essential to combat DENV and
ZIKV infection. The maturation and potency of this response is
known to define to a great extent the infection outcome11,47.




































Fig. 2 Previous ZIKV immunity does not contribute to an increase of DENV RNAemia. a DENV-2 RNA kinetics in ZIKV-immune and naive animals at
baseline, day 1–10, and day 15 after DENV infection. RNA genome copies (Log10) per milliliter of serum were measured by qRT-PCR. Symbols represent
individual animals per cohort: blue squares (ZIKVPF-10mo), orange squares (ZIKVPR-2mo), and black circles (naive). Box and whiskers show the
distribution of log-transformed values per group per timepoint. Boxes include the mean value per group, while whiskers depict the minimum and maximum
values for each group. Cutted line mark the limit of detection (20 genomes copies). Statistically significant differences between groups were determined
using two-way ANOVA adjusted for Tukey’s multiple comparisons test including 12 families, and 3 comparisons per family. b The total days that DENV-2
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Fig. 3 ZIKV immunity does not exacerbate levels of pro-inflammatory cytokines. Cytokines and chemokines expression levels were determined in serum
(pg/ml) by multiplex bead assay (Luminex) at baseline, 1, 2, 3, 5, 10, 15, and 30 days after DENV infection. The panel includes: a interferon alpha (IFN-α),
b interleukin-6 (IL-6), c monokine induced by IFN-gamma (MIG/CXCL9), d monocyte chemoattractant protein 1 (MCP-1/CCL2), e macrophage
inflammatory protein 1-beta (MIP-1β/CCL4), f IL-1 receptor antagonist (IL-1RA), g C–X–C motif chemokine 10 (CXCL10/IP-10), and h perforin. Symbols
connected with lines represent mean expression levels detected of each cytokine/chemokine per cohort over time: blue squares (ZIKVPF-10mo), orange
squares (ZIKVPR-2mo), and black circles (naive). Error bars indicate the standard error of the mean (SEM) for each cohort per timepoint. Cutted line
marks the limit of detection for each individual cytokine/chemokine. Statistically significant differences between groups were calculated using two-way
ANOVA adjusted for Tukey’s multiple comparisons test including eight families, and three comparisons per family. Significant multiplicity adjusted p-values
(*< 0.05, **< 0.01, ***<0.001, ****< 0.0001) are shown colored representing the cohort against that particular point where is a statistically significant
difference between groups. Source data are provided as a Source Data file
Accordingly, we tested the neutralization capacity of NAbs in
serum from ZIKV-immune and naive animals before and after
DENV infection, to determine whether an early convalescence or
mid convalescence to ZIKV affected the NAb response. Plaque
reduction neutralization test (PRNT) was performed to elucidate
the NAb titers of all groups against all DENV serotypes and both
ZIKV pre-infecting strains. Before infection with DENV, the
naive groups had no detectable NAb levels (< 1:20 PRNT60 titers)
against all DENV serotypes, while ZIKV-immune groups showed
low cross-NAb titers against DENV-2 and DENV-4 (Fig. 4a).
These cross-reactive levels were higher in the ZIKVPF-10mo
group than in the ZIKVPR-2mo group for both viruses. The peak
of high NAb titers occurred at 30 days after DENV infection for
all groups (ZIKVPF-10mo > ZIKVPR-2mo > naive) against all
DENV serotypes (DENV-2 > DENV-4 > DENV-3 > DENV-1)
(Fig. 4b). The ZIKVPF-10mo group neutralized all DENV ser-
otypes with significant higher potency than naive animals (p <
0.0001, p= 0.0337, p < 0.0001, p < 0.0001 for DENV1-4; two-way
ANOVA Tukey test) and the ZIKVPR-2mo group, except for
DENV-2, that both ZIKV-immune groups have comparable
neutralization magnitude at 30 dpi (p= 0.0002, p= 0.7636, p=
0.0016, p= 0.0004 for DENV1-4; two-way ANOVA Tukey test).
However, the neutralization kinetics by sigmoidal response curves
suggest higher percent of neutralization against DENV-2 over-
time in the group with mid convalescence to ZIKV (Supple-
mentary Fig. 4). On the other hand, the ZIKVPR-2mo group
showed significantly higher potency of the NAb response only
against DENV-1 compared with naive animals (p= 0.0146; two-
way ANOVA Tukey test) (Fig. 4b).
In addition, we tested whether the NAb titers that peak at
30 dpi for all groups remain constant over time (up to 90 dpi)
against all DENV serotypes (Fig. 4c–f). In general, the neutraliz-
ing response of the ZIKVPF-10mo group maintained higher NAb
titers up to 90 dpi compared with ZIKVPR-2mo and naive
groups. Significant differences between ZIKVPF-10mo and
ZIKVPR-2mo groups were observed against DENV-1, -3, and
-4 at day 30 pi (p= 0.0002, p= 0.0016, p= 0.0004; two-way
ANOVA Tukey test) and at day 60 pi against DENV-2 and
DENV-3 (p= 0.0179, p= 0.0047; two-way ANOVA Tukey test).
The NAb response of the ZIKVPF-10mo group was even more
significantly higher compared with the naive group at day 15
(only performed for the infecting serotype to monitor early
neutralizing activity), day 30, 60, and 90 pi against DENV-2 (p=
0.0022, p= 0.0337, p= 0.0146, p= 0.0337; two-way ANOVA
Tukey test); at day 30 pi against DENV-1 (p < 0.0001, two-way
ANOVA Tukey test); at day 30 and 60 pi against DENV-3 (p <
0.0001, two-way ANOVA Tukey test); and at day 30 pi against
DENV-4 (p < 0.0001, two-way ANOVA Tukey test). In contrast,
the ZIKVPR-2mo group showed a NAb response with a
magnitude and long-lasting levels comparable with the naive
group, except at day 15 and 30 pi against DENV-2 and DENV-1,
respectively (p= 0.0067, p= 0.0146; two-way ANOVA Tukey
test). The NAb response was long-lasting in the ZIKVPF-10mo
group compared with other groups as supported by the data from
days 30 and 60 p.i. At day 90 pi, although no significant
differences were observed between all groups, the ZIKVPF-10mo
group showed a consistent trend to maintain higher NAb titers
against all DENV serotypes, indicating a higher and long-lasting
breadth of cross-neutralization within DENV serocomplex.
Collectively, these results demonstrate that a mid convales-
cence to ZIKV provokes a boost of the magnitude and durability
of the Ab response against all DENV serotypes more effectively
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Fig. 4 Neutralization of DENV serotypes by ZIKV-immune animals is higher in magnitude. The magnitude of the neutralizing antibody (NAb) response was
determined (a) before and (b) 30 days after DENV infection by plaque reduction neutralization test (PRNT) against all DENV serotypes. c–f The durability
of the neutralizing response was assessed measuring NAb titers up to 90 dpi against all DENV serotypes. Symbols connected with full lines indicate mean
levels of NAb titers detected per cohort over time: blue squares (ZIKVPF-10mo), orange squares (ZIKVPR-2mo), and black circles (naive). Error bars
represent the standard error of the mean (SEM). PRNT60: NAb titer capable of reduce 60% or more of DENV serotypes plaque-forming units (pfu)
compared with the mock (control of virus without serum). A PRNT60 1:20 titer was considered positive, and < 1:20 as a negative Neut titer. Dotted line
mark < 1:20 for the negative results. Non-neutralizing titers (< 1:20) were assigned with one-half of the limit of detection for graphs visualization (1:10).
Statistically significant differences between groups were calculated using two-way ANOVA adjusted for Tukey’s multiple comparisons test including four
and six families for heterologous serotypes and DENV-2, respectively, and three comparisons per family. Significant multiplicity adjusted p-values (*< 0.05,
**< 0.01, ***< 0.001, ****< 0.0001) are shown. Blue and orange asterisks represent significant difference between the corresponded ZIKV immune groups
and naive group, and gray asterisks indicate a significant difference between ZIKV immune groups. Source data are provided as a Source Data file
than in animals with an early convalescence to ZIKV, but also
higher compared with a de novo DENV-specific NAb response of
the naive animals.
ZIKV neutralization is boosted by DENV infection. Previous
exposure to ZIKV strains in ZIKV-immune groups developed
high levels of cross-reactive, non-neutralizing, and NAbs before
DENV infection (baseline). To determine if this memory Ab
response is strain-specific and if the difference in convalescence
period to ZIKV alters the efficacy and modulation after DENV
infection, we assessed the NAb levels in ZIKV-immune (ZIKVPF-
10mo and ZIKVPR-2mo) and ZIKV-naive serum with both
pre-infecting contemporary Asian-lineage H/PF/2013 and
PRVABC59 ZIKV strains at multiple timepoints after DENV
infection. At baseline, both ZIKV-immune groups showed high
NAb titers against H/PF/2013 strain, which suggest that irre-
spective of pre-exposure to different ZIKV strains and different
convalescent periods the Ab response remains similarly effective
(Fig. 5a). As early as day 15 after DENV infection, a potent boost
of NAb titers in both ZIKV-immune groups was developed.
However, elevated NAb titers were significantly higher in the
ZIKVPF-10mo group compared with the ZIKVPR-2mo and
naive groups at day 15 pi (p= 0.0005, p < 0.0001; two-way
ANOVA Tukey test) and day 30 pi (p= 0.0067, p= 0.0012; two-
way ANOVA Tukey test). As expected, this elevated ZIKV cross-
reactive NAb levels decreased gradually overtime after 15 dpi in
both ZIKV-immune groups. Nevertheless, the ZIKVPF-10mo
group retained higher NAb titers until 90 dpi, while the titers of
the ZIKVPR-2mo group returned to baseline levels. Of note, the
NAb titers of the naive group were considered as negative in all
timepoints and failed to neutralize ZIKV throughout DENV
infection even at concentrated levels of the Abs (Fig. 5a). These
results are confirmed by the behavior of neutralization kinetics by
sigmoidal response curves where the ZIKVPF-10mo group
retained elevated magnitude of ZIKV neutralization overtime
(Supplementary Fig. 5).
To determine if the immune memory induced by different
ZIKV strains play a role in the modulation of the cross-NAb
response triggered by a subsequent DENV infection, NAb titers
were measured against both ZIKV strains before and 30 days after
DENV infection. The ZIKVPF-10mo group showed significant
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Fig. 5 ZIKV neutralization is boosted after DENV infection, and is strain independent. a NAb titers against ZIKV H/PF/2013 were determined by PRNT60
at baseline, 7, 15, 30, 60, and 90 days after DENV infection. Comparison of NAb titers between pre-infecting ZIKV strains was performed (b) before and
(c) after DENV infection. Symbols connected with full lines indicate mean levels of NAb titers detected per cohort over time: blue squares (ZIKVPF-10mo),
orange squares (ZIKVPR-2mo), and black circles (naive). Error bars represent the standard error of the mean (SEM). PRNT60: NAb titer capable of reduce
60% or more of ZIKV strains plaque-forming units (pfu) compared with the mock (control of virus without serum). A PRNT60 1:20 titer was considered
positive, and < 1:20 as a negative Neut titer. Dotted line mark < 1:20 for negative results. Non-neutralizing titers (< 1:20) were assigned with one-half of the
limit of detection for graphs visualization (1:10). Statistically significant differences between groups were calculated using two-way ANOVA adjusted for
Tukey’s multiple comparisons test including six and two families for panel a and b, c, respectively, and three comparisons per family. Significant multiplicity
adjusted p-values (*< 0.05, **< 0.01, ***< 0.001, ****< 0.0001) are shown. Blue and orange asterisks represent significant difference between the
corresponded ZIKV-immune groups and naive group, and gray asterisks indicate a significant difference between ZIKV-immune groups. Source data are
provided as a Source Data file
higher NAb titers against both ZIKV strains compared with the
ZIKVPR-2mo group before DENV infection (p= 0.0093, p=
0.0141; two-way ANOVA Tukey test) (Fig. 5b). Subsequently,
DENV infection promote an equally eight-fold increase of NAb
titers against both strains in the ZIKVPF-10mo group, signifi-
cantly higher than the four-fold increase in the ZIKVPR-2mo
group (p= 0.0025, p= 0.0011; two-way ANOVA Tukey test)
(Fig. 5c). To rule out that difference in fitness between both ZIKV
strains would bias the magnitude of the NAbs after DENV
infection, we compared in parallel the NAb titers at 30 and
60 days after ZIKV infection (day 60 corresponds to the baseline
of the ZIKVPR-2mo group). No significant differences were
observed between ZIKV-immune groups in the NAb titers
induced by both strains at the same timepoints after ZIKV
infection (Supplementary Fig. 6). Altogether, these results
demonstrate that DENV infection results in a significant increase
in the magnitude and durability of the cross-NAb response
against ZIKV in animals with a mid-convalescent period from
ZIKV infection. The elicited changes in neutralization capacity
were likely driven more by the longevity of the immune memory
maturation and the associated memory recall of the ZIKV
immunity than by a strict dependency of the specific pre-exposed
ZIKV strain.
Immune cell subsets modulated by ZIKV immunity. We per-
formed immunophenotyping by flow cytometry to assess the
frequency, early activation, and proliferation of multiple immune
cell subsets, and how these parameters are affected by the pre-
sence of pre-existing immunity to ZIKV on a subsequent DENV
infection (Supplementary Figs. 7, 8, and 9 for gating strategy;
Supplementary Table 2 for Ab panel). As part of the innate
immune response, the frequency of dendritic cells (DCs) and
natural killer (NK) cells subpopulations were measured. Plas-
macytoid DCs (pDCs: Lin−HLA-DR+CD123+) are known to
respond to viral infection by production of IFN-α, while myeloid
DCs (mDCs: Lin−HLA-DR+CD11c+) interacts with T cells. The
frequency of pDCs was not significantly altered by DENV
infection in any group compared with baseline levels (Supple-
mentary Fig. 10a). At day 2 pi, we detected a significant increase
of mDCs in the ZIKVPF-10mo group (p= 0.0082; two-way
ANOVA Dunnett test) (Supplementary Fig. 10b). Furthermore,
we determined the frequency of NK subpopulations including:
NKCD8, NKCD56, NKp30, and NKp46 (Supplementary Fig. 11).
In general, no differences were detected between baseline and
after DENV infection in all groups for all NK subpopulations and
receptor expression with the exception of the ZIKVPR-2mo
group that showed a significant increases in the following
subpopulations: NKG2A+NKp30 and NKp30+NKp46+ at 7 dpi
(p= 0.0495, p= 0.0006; two-way ANOVA Dunnett test) and
NKp46+NKp30+ at 7 and 10 dpi (p= 0.0005, p= 0.0001; two-
way ANOVA Dunnett test) (Supplementary Fig. 11j, o, s).
We next investigated cell subsets that are part of the bi-phasic
(humoral/cellular) adaptive immune response such as B (CD20+
CD3-) and T (CD3+CD20-) cells. No differences were detected in
the total B cells between groups following DENV infection
compared with baseline levels (Supplementary Fig. 12a), but
ZIKV-immune groups had elevated levels of activated B cells
(CD20+CD3-CD69+) since baseline and a trend to increase these
levels more than the naive group overtime (Supplementary Fig. 12b).
We detected a significant decrease of proliferating B cells (CD20+
CD3-Ki67+ ) in naive animals at 7 and 10 dpi (p= 0.0031, p=
0.0345; two-way ANOVA Dunnett test), while ZIKV-immune
groups retained their proliferating levels (Supplementary Fig. 12c).
Interestingly, the ZIKVPF-10mo group showed a significant
increase of B cells that were proliferating and activated
simultaneously (CD20+CD3-CD69+Ki67+ ) as early as in day
1 pi (p= 0.0240; two-way ANOVA Dunnett test) and maintained
higher levels up to 10 dpi (Supplementary Fig. 12d). Together, these
phenotyping results of B cells are consistent with the early and
boosted production of binding and NAbs in the ZIKVPF-10mo
group compared with naive animals. The frequency of the total
T cells (CD3+CD20−) and CD4+/CD8+ T-cell subsets was
comparable at all timepoints before and after DENV infection in
all groups of animals (Supplementary Fig. 13a–c).
Previous studies have demonstrated that DENV- and ZIKV-
specific CD4+ and CD8+ T cells are enriched in certain
memory subsets23,48. Thus, we measured whether the early
activation of T-cell subpopulations, such as effector memory
(CD3+CD4+CD28−CD95+) and central memory (CD3+
CD4+CD28+CD95+) T cells (T-EM and T-CM), within each
T-cell compartment was modulated following DENV infection in
presence or absence of convalescence to ZIKV (Fig. 6; Supple-
mentary Fig. 7 for gating strategy). The ZIKVPF-10mo group
showed a significant higher frequency of activated CD4+
and CD8+ T-EM (CD3+CD4+CD28−CD95+CD69+ and CD3+
CD8+CD28−CD95+CD69+) following DENV infection com-
pared with basal levels (CD4+ T-EM at 7 and 10 dpi: p= 0.0001,
p= 0.0072; CD8+ T-EM at 2 and 7 dpi: p= 0.0291, p= 0.0001;
two-way ANOVA Dunnett test) (Fig. 6a, d). Interestingly, the
ZIKVPR-2mo group showed a very limited frequency and
activation of the CD4+ and CD8+ T-EM compared with the
ZIKVPF-10mo and naive groups. However, this group with an
early convalescent period to ZIKV, contrary to the other two
groups, showed a very limited but significant activation of CD8+
T-CM (CD3+CD8+CD28+CD95+CD69+) at day 7 and 10 pi (p
= 0.0007, p= 0.0147; two-way ANOVA Dunnett test) (Fig. 6e).
In contrast, naive animals did not show any significant activation
of these memory cell subsets after DENV infection. Collectively,
these results suggest that following DENV infection: (i) animals
with a mid-convalescence ZIKV immunity have a more dynamic
B-cell response, and are able to rapidly produce more activated
effector memory T cells from both T-cell compartments; (ii)
animals with an early convalescence to ZIKV induce activation of
T-CM in the CD8+ compartment with a very limited T-EM
frequency and activation profile compatible with a contraction
phase of the T cell compartments; (iii) and animals without
previous exposure to ZIKV exhibit a limited B-cell response and
minimal modulation of memory T cell subpopulations at early
timepoints as the ZIKV-immune groups.
T cell functional response is shaped by ZIKV immunity. To
further characterize the cross-reactive T cell response, we inves-
tigated if different convalescent periods of ZIKV immunity
impacted the outcome of the effector role of CD4+ and CD8+
T cells following DENV infection. PBMCs were isolated and
stimulated with peptide pools from DENV and ZIKV envelope
(E) proteins and from ZIKV nonstructural proteins (ZIKV–NS)
(Supplementary Table 4 for peptide sequences). Then, intracel-
lular cytokine staining using flow cytometry analysis (Supple-
mentary Fig. 14 for gating strategy; Supplementary Table 3 for Ab
panel) was performed to quantify the production of effector
immune markers, such as the cytotoxic marker CD107a, IFN-γ,
and TNF-α by CD4+ and CD8+ T cells at baseline, 30, 60, and
90 days after DENV infection (Fig. 7).
To assess the ZIKV-primed specific- or cross-reactive effector
T cell response, we studied the response against ZIKV or DENV
stimuli before DENV infection. In general, before DENV
infection, we found that the ZIKV-primed effector T cell response
was higher in CD8+ (Fig. 7m, q, u) than in CD4+ (Fig. 7a, e, i)
T cells. Of note, significant higher levels of CD107a, INF-γ, and
TNF-α-producing CD8+ T cells were found only in the ZIKVPF-
10mo group before DENV infection (ZIKVPF-10mo vs ZIKVPR-
2mo for CD107a: p= 0.0002; ZIKVPF-10mo vs naive for
CD107a: p= 0.0401; ZIKVPF-10mo vs ZIKVPR-2mo for INF-γ:
p= 0.0020; ZIKVPF-10mo vs ZIKVPR-2mo for TNF-α: p=
0.0033; ZIKVPF-10mo vs naive for TNF-α: p= 0.0354; two-way
ANOVA Tukey test) (Fig. 7m, q, u). This basal effector response
of CD8+ T cells in the ZIKVPF-10mo group is predominated by
cross-reactive CD8+ T cells against DENV E protein. Very
low effector T cell response against ZIKV NS proteins was
detected for all groups (ZIKVPF-10mo > ZIKVPR-2mo > naive).
In summary, results of T cell functional response before DENV
infection suggest that a mid convalescence to ZIKV provoke a
higher CD8+ T cell effector response capable to cross-react
efficiently with DENV E protein.
After DENV infection, we were able to determine the
modulation of the ZIKV-primed effector CD4+ and CD8+ T cell
responses of ZIKV-immune groups and the de novo response of
ZIKV-naive animals. The ZIKVPF-10mo and naive groups
significantly boosted their CD107a expression in both T-cell
compartments stimulated mainly by DENV E protein at 30 and up
to 90 days after DENV infection (CD4+ T cells: ZIKVPF-10mo vs
ZIKVPR-2mo: p < 0.0001 at 30 dpi, p < 0.0001 at 60 dpi; naive vs
ZIKVPR-2mo: p < 0.0001 at 30 dpi, p= 0.0018 at 60 dpi; ZIKVPF-
10mo vs Naïve: p= 0.0204 at 30 dpi. CD8+ T cells: ZIKVPF-10mo
vs ZIKVPR-2mo: p < 0.0001 at 30 dpi, p < 0.0001 at 60 dpi,
p= 0.0008 at 90 dpi; naive vs ZIKVPR-2mo: p= 0.0039 at 30 dpi,
p < 0.0001 at 60 dpi; p= 0.0081 at 90 dpi; ZIKVPF-10mo vs naive:
p= 0.0194 at 30 dpi; two-way ANOVA Tukey test) (Fig. 7b, c, n,
o, p). Also, these groups boosted the CD107a cytotoxic signature
reacting against ZIKV E and NS proteins by cross-reactive CD4+
T cells 30 days after DENV infection (ZIKVPF-10mo vs ZIKVPR-
2mo: p= 0.0025 for ZIKV E, p < 0.0001 for ZIKV NS; Naïve vs
ZIKVPR-2mo: p= 0.0025 for ZIKV E, p= 0.0002 for ZIKV NS;
two-way ANOVA Tukey test) (Fig. 7b).
The ZIKVPF-10mo group showed a remarkable significant
increase of the IFN-γ-producing CD4+ T cells against DENV E
protein since 60 dpi and is maintained up to 90 dpi compared
with other groups (ZIKVPF-10mo vs ZIKVPR-2mo at 60 and 90
dpi: p < 0.0001, p= 0.0024; ZIKVPF-10mo vs Naïve at 60 and
90 dpi: p < 0.0001, p= 0.0037; two-way ANOVA Tukey test)
(Fig. 7g, h), and was the only group with significant increase in
the IFN-γ-producing CD8+ T-cell compartment at 60 dpi
(ZIKVPF-10mo vs ZIKVPR-2mo: p= 0.0253; two-way ANOVA
Tukey test) (Fig. 7s). On the other hand, the ZIKVPR-2mo group
exhibited a significant increase of IFN-γ-producing CD4+ T cells
earlier than other groups at 30 dpi (ZIKVPR-2mo vs ZIKVPF-
10mo: p < 0.0001; ZIKVPR-2mo vs naive: two-way ANOVA
Tukey test) (Fig. 7f). Interestingly, the naive group showed an
increase of cross-reactive TNF-α-producing CD4+ T cells against
ZIKV NS proteins 30 days after DENV infection (naive vs
ZIKVPR-2mo: p= 0.0359; two-way ANOVA Tukey test) (Fig. 7j).
The ZIKVPF-10mo group developed a significant effector T cell
response by TNF-α-producing CD4+ T cells against DENV and
ZIKV E proteins at 60 days after DENV infection (ZIKVPF-10mo
vs ZIKVPR-2mo against DENV/ZIKV E protein: p= 0.0163, p=
0.0172; two-way ANOVA Tukey test) (Fig. 7k). Although all
groups showed a boosted TNF-α effector response in the
CD8+ T cell compartment up to 90 days after DENV infection,
no significant differences between groups were observed.
Collectively, these results after DENV infection suggest that a
mid convalescence to ZIKV translate in a more complete
functional T cell response characterized by: (i) a cytotoxic
CD107a+ phenotype directed to DENV E protein for both T-
cell compartments comparable with the DENV-specific de novo
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Fig. 6 Activation of effector and central memory CD4+ and CD8+ T cells after DENV infection. Activation (CD69+) of effector memory (T-EM: CD3+
CD4+CD28−CD95+) and central memory (T-CM: CD3+CD4+CD28+CD95+) T cells within (a–c) CD4+ and (d–f) CD8+ T-cell compartments before and
after DENV infection. Percent of cells were determined by immunophenotyping using flow cytometry (Supplementary Fig. 7 for gating strategy). Blue,
orange, and black squares represent T-EM for ZIKVPF-10mo, ZIKVPR-2mo, and naive, respectively. Gray squares represent T-CM for each group. Short
black lines mark mean value for each group per timepoint. Cutted line divide % of T-EM and T-CM cells quantified before and after DENV infection.
Statistically significant differences within groups were determined using two-way ANOVA adjusted for Dunnett’s multiple comparisons test (comparison
of each group response at each timepoint versus baseline of the same group) including two families, and seven comparisons per family. Significant
differences are reported as multiplicity adjusted p-values (*< 0.05, **< 0.01, ***< 0.001, ****< 0.0001). Asterisks represent significant difference between
the corresponded timepoint and baseline within the same group. Source data are provided as a Source Data file
TNF-α-producing CD8+ T-cell effector response that cross-
react efficiently with DENV E protein since baseline, and is
boosted after DENV infection, (iii) and promoted the higher
T cell effector response against ZIKV NS proteins. An early
convalescence to ZIKV results in (iv) a very limited cytotoxic
activity (limited expression of CD107a marker) which is in line
with a very limited activation of the T-EM, and with failed
capability to react efficiently against E or NS proteins. The
ZIKV-naive group response was characterized by: (v) produc-
tion of a DENV-specific de novo functional T cell response with
similar magnitude between both T cell compartments, (vi)
capable to cross-react against ZIKV E and NS proteins, (vii)
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Fig. 7 Longevity of ZIKV immunity shapes the T cell functional response. T cell functional effector response was determined by the quantification (%) of
(a–d; m–p) CD107a-expressing and (e–h; q–t) IFN-γ or (i–l; u–x) TNF-α-producing CD4+ and CD8+ T cells before (0) and 30, 60, and 90 days after DENV
infection. Responses to several peptide pools that encode for DENV and ZIKV envelope (E) proteins or ZIKV nonstructural (NS) protein were quantified.
After antigenic stimulation, intracellular cytokine staining was performed using flow-cytometry analysis (Supplementary Fig. 14 for gating strategy).
Individual symbols represent each animal per antigenic stimulation over time: blue squares (ZIKVPF-10mo), orange squares (ZIKVPR-2mo), and black
circles (naive). Short gray lines mark mean value for each group. Statistically significant differences between groups were calculated using two-way
ANOVA adjusted for Tukey’s multiple comparisons test including three families, and three comparisons per family. Significant multiplicity adjusted
p-values (*< 0.05, **< 0.01, ***< 0.001, ****< 0.0001) are shown. Asterisks represent significant difference between indicated groups. Source data are
provided as a Source Data file
Discussion
We found that previous ZIKV infection modulates the immune
response against subsequent DENV infection without an
enhancement of DENV viremia nor pro-inflammatory status.
This modulation is influenced by the longevity of ZIKV con-
valescence—more after longer ZIKV pre-exposure (Supplemen-
tary Discussion: Findings summary).
The aftermath of the recent ZIKV epidemic has been related to
a remarkable decrease in DENV cases in Brazil27, and also in
most of Latin American and Caribbean countries (http://www.
paho.org/data/index.php/es/temas/indicadores-dengue/dengue-
nacional/9-dengue-pais-ano.html?start=2)24. To evaluate the
hypothesis of a potential ZIKV–DENV cross-protection in
humans will be necessary to characterize the immunological
history of prospective cohorts45, but human samples for this
purpose are scarce yet. Because of this, NHPs are key to provide
knowledge and anticipate different immunological scenarios
when DENV epidemics re-emerge in human populations with
previous immunity to ZIKV.
Animals with pre-existing ZIKV immunity do not show an
enhancement of DENV-induced RNAemia. Previous ZIKV
immunity is associated with a trend of less RNAemia days
during subsequent DENV infection. This effect is more evident
in animals with a ZIKV convalescence period of 10 months.
Previous work reported that a period of early convalescence
(56 days) to ZIKV (PRVABC59 strain) in rhesus macaques was
associated with a significant increase of DENV-2 RNAemia at
day 5 after DENV infection and a pro-inflammatory cytokine
profile. However, very similar to our results, it was noteworthy a
delay at early timepoints and an early clearance in late time-
points of the DENV-2 RNAemia in ZIKV-immune macaques in
comparison to the naive ones37. Several factors may account for
differences in the DENV RNAemia and pro-inflammatory status
between early ZIKV convalescent cohorts in both studies, such
as DENV strains, sample types, animals genetic heterogeneity,
and cytokine panels (Supplementary Discussion: DENV
RNAemia, Cytokine profile).
Due to limited availability of ZIKV-immune cohorts, we used
animals infected with two different ZIKV strains for our sub-
sequent challenge with DENV-2. However, extensive revision of
the literature up-to-date reveals a broad consensus that these two
contemporary ZIKV strains behave very similar from an antigenic
point of view11,49–51. ZIKV strains were neutralized with same
efficacy within each ZIKV-convalescent group, explained by the
broadly neutralization activity against multiple ZIKV strains
irrespective of the infecting strain50. However, the magnitude of
the neutralization against both strains was statistically higher in
animals exposed to DENV 10 months (mid convalescence) after
ZIKV infection. These results suggest that the differences in the
neutralization profile between the two ZIKV-immune groups
are associated to the longevity of ZIKV convalescence, which may
be attributable to the maturation of the cross-reactive immune
memory elicited by the heterologous DENV infection and not to
the antigenic differences or the different replication capabilities in
rhesus macaques of those two pre-infecting ZIKV strains16,52.
The period of convalescence further had an impact in the
maintenance of the neutralization magnitude against ZIKV and
DENV overtime. We observed a higher activation of the memory
immune response characterized by transiently higher peak levels
of serum NAbs against DENVs and ZIKV in ZIKVPF-10mo
immune animals compared with ZIKVPR-2mo immune animals
challenged with DENV-2. These results show the ability of
DENV-2 to activate memory B cells (MBCs) stimulated by the
previous ZIKV infection, but this activation is modest and short-
lived compared with the robust and sustained activation of MBCs
on secondary DENV infections10,30,46,53. On the other hand,
ZIKV NAbs decay overtime in ZIKV-immune animals after
DENV infection, but animals with longer convalescence retain
higher titers until the end of the study. Overall, these results
demonstrate that pre-existing ZIKV immunity leads to a transient
increase in NAb responses in animals challenged with DENV-2
compared with naive animals. This is in contrast with previous
findings were ZIKV-convalescent macaques show a lack of an
early and delayed anamnestic response overtime with limited
induction of DENV NAbs compared with ZIKV-naive animals
after DENV infection54. Interestingly, ZIKV-convalescent ani-
mals showed some degree of cross-neutralization against DENV-
2 and DENV-4 before DENV infection, which is in line with
previous findings in NHPs and humans (Supplementary Dis-
cussion: Neutralizing antibody response)16,55.
T cells from DENV immunity are being implicated in mediating
cross-protection against ZIKV21–23, but their role and kinetics in
the ZIKV–DENV scenario are poorly understood. We found that
animals with a mid-convalescence to ZIKV developed an early
activation of CD4+ and CD8+ effector memory T cells after DENV
infection, similar to findings of DENV–ZIKV opposite scenario in
humans23. On the other hand, the ZIKV early-convalescent group
displays a modest activation (T-CM>T-EM) early after DENV
infection associated with a possible contraction phase (Supple-
mentary Discussion: T cells phenotyping)56,57. Moreover, we
observed an IFN-γ phenotype of the functional response of CD8+
T cells in animals with longer convalescence to ZIKV, which has
been identified also in ZIKV-convalescent humans58, and early after
DENV challenge in DENV-vaccinated subjects protected from
severe disease59,60. Strikingly, this response recognizes more effi-
ciently peptides from DENV E protein than from ZIKV E protein
(Supplementary Discussion: T cells functional response). In addi-
tion, an increased cytotoxic profile by CD107a-expressing CD4+
and CD8+ T cells in the ZIKV mid-convalescent group correlates
with the early activation of CD4+ and CD8+ effector memory
T cells and elevated levels of perforin release. Memory CD4+ T cells
are required to generate an effective humoral response against
ZIKV61. Based on this, the higher proportion of DENV-E-reactive
IFN-γ-producing CD4+ T cells may play a role in the induction of
the robust Ab response in the ZIKV mid-convalescent group
against ZIKV and all DENV serotypes.
One limitation of our study is the utilization of low numbers of
animals per group. However, fundamental and seminal con-
tributions on ZIKV and ZIKV/DENV interactions have been
obtained by using similar limited number of animals per
group16,17,62,63. Another limitation is that our study monitored
the immune response up to 90 days after DENV infection.
Additional longitudinal studies are needed to test the immune
response over longer periods of time, including subsequent
DENV heterotypic challenges to evaluate the efficacy of the
memory recall in cross-protection between serotypes. Finally, we
cannot comment about the likelihood to increase or decrease
susceptibility to develop DHF/DSS in the context of ZIKV
immunity since DENV clinical manifestations in NHP models are
limited and are characterized to be subclinical infections28.
This study reinforces the usefulness of NHPs as a suitable model
to characterize the immune response elicited by heterologous fla-
vivirus infections. Our findings of highly cross-reactive response
against DENV in presence of previous ZIKV immunity with no
exacerbation of DENV pathogenesis may contribute to explain the
decrease of detected DENV cases after ZIKV epidemic in the
Americas. This scenario has been suggested recently using a fewer
number of animals38. Furthermore, our data show a positive sce-
nario that supports the implementation of ZIKV vaccine programs,
since it suggests that a vaccine-acquired ZIKV-immunity may not
worsen DENV pathogenesis, and may ameliorate immune response
against a subsequent infection with DENV. Similarly, the
implementation of DENV vaccines is also supported in the context
of previous ZIKV immunity, since ZIKV convalescence may boost
the vaccine-acquired anamnestic immune response to DENV
without predisposing to an enhanced pathogenesis. However, the
selection of the vaccine schedule may be critical to induce the
optimal immune response when more than one doses are planned.
Methods
Cell lines. Aedes albopictus cells, clone C6/36 (ATCC CRL-1660), whole mosquito
larva cells, were maintained in the Dulbecco Minimum Essential Medium (DMEM)
(GIBCO, Life Technologies) supplemented with 10% fetal bovine serum (FBS)
(Gibco) and 1% penicillin/streptomycin (P/S) (Gibco). C6/36 were used to produce
previous ZIKV and DENV viral stocks with high titers in 150–175 cm2 cell culture
flasks (Eppendorf), and incubated at 33 °C and 5% CO2. Vero cells, clone 81 (ATCC
CCL-81), and African green monkey kidney epithelial cells were maintained with
DMEM supplemented with 10% FBS and 1% of P/S, HEPES, L-glutamine, and
nonessential amino acids (NEAA) in 75 cm2 cell culture flasks, and incubated at 37 °C
and 5% CO2. Vero-81 cells were used for the cells monolayer in viral titrations by
plaque assays and PRNT in flat bottom 24-well plates (Eppendorf).
Viral stocks. The DENV-2 New Guinea 44 (NGC) strain (kindly provided by Steve
Whitehead, NIH/NIAID, Bethesda, MD, USA), known to replicate well in rhesus
macaques, was used for the challenge in order to obtain comparative results with
previous published studies from our group on DENV and ZIKV challenge
studies16,33. We have standardized the assays to quantify this virus by Plaque assay,
as described in our previous work16. The titer of DENV-2 for the challenge was 5 ×
107 pfu/ml. In addition, ZIKV H/PF/2013 strain (kindly provided by CDC-Dengue
Branch, San Juan, Puerto Rico), ZIKV PRVABC59 (ATCC VR-1843), DENV-1
Western Pacific 74, DENV-3 Sleman 73, and DENV-4 Dominique strains (kindly
provided by Steve Whitehead from NIH/NIAID, Bethesda, MD, USA) were pro-
pagated in C6/36 cells, titrated, and used for PRNT assays.
Viral titration plaque assay. DENV titrations by plaque assay were performed
seeding Vero-81 (~8.5 × 104 cells/well) in flat bottom 24-well cell culture well plates
(Eppendorf) in supplemented DMEM the day before. Viral dilutions (tenfold) were
made in diluent media [Opti-MEM (Invitrogen) with 2% FBS (Gibco) and 1% P/S
(Gibco)]. Prior to inoculation, growth medium was removed and cells were
inoculated with 100 µl/well of each dilution in triplicates. Plates were incubated for
1 h, 37 °C, 5% CO2 and rocking. After incubation, virus dilutions were overlaid
with 1 ml of Opti-MEM [1% carboxymethylcellulose (Sigma), 2% FBS, 1% of
NEAA (Gibco), and P/S (Gibco)]. After 3–5 days of incubation (days vary between
DENV serotypes), overlay was removed and cells were washed twice with phos-
phate buffered saline (PBS), fixed in 80% methanol (Sigma) in PBS, and incubated
at room temperature (RT) for 15 min. Plates were blocked with 5% nonfat dry milk
(Denia) in PBS for 10 min. Blocking buffer was discarded and 200 µl/well of pri-
mary antibodies mix [anti-E protein monoclonal antibody (mAb) 4G2 and anti-
prM protein mAb 2H2 (kindly provided by Aravinda de Silva and Ralph Baric,
University of North Carolina Chapel Hill, NC, USA), both diluted 1:250 in
blocking buffer] were added and incubated for 1 h, 37 °C, 5% CO2 and rocking.
Plates were washed twice with PBS and incubated in same conditions with
horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary antibody
(Sigma), diluted 1:1000 in blocking buffer. Plates were washed twice with PBS, and
150 µl/well of TrueBlue HRP substrate (KPL) were added, and plates were incu-
bated from 1 to 10 min at RT until plaque-forming units (pfu) were produced and
visible. Then 200 µl/well of distilled water were added to stop the substrate reaction,
plates get dry, and pfu were counted to calculate viral titers.
Macaques and viral challenge. From 2008 to 2015, the Caribbean Primate
Research Center (CPRC) funded a large DENV research program. Multiple studies
made available several cohorts of rhesus macaques (Macaca mulatta) infected with
different DENV serotypes in distinct timelines, and also naive cohorts were
available as well. After our laboratories prioritized ZIKV research since 2016,
DENV pre-exposed and naive cohorts were infected with ZIKV and pre-exposed
animals became available for this study. All animals were housed within the
Animal Resources Center facilities at the University of Puerto Rico-Medical Sci-
ences Campus (UPR-MSC), San Juan, Puerto Rico. All the procedures were per-
formed under the approval of the Institutional Animal Care and Use Committee
(IACUC) of UPR-MSC and in a facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC file # 000593;
Animal Welfare Assurance number A3421; protocol number, 7890116). Proce-
dures involving animals were conducted in accordance with USDA Animal Wel-
fare Regulations, the Guide for the Care and use of Laboratory Animals and
institutional policies to ensure minimal suffering of animals during procedures. All
invasive procedures were conducted using anesthesia by intramuscular injection of
ketamine at 10–20 mg kg−1 of body weight. Rhesus macaques from the CPRC are
very well genetically characterized from a common stock introduced in 1938 at
Cayo Santiago, an islet located in the southeast of Puerto Rico. These macaques
with Indian genetic background are part of the purest colony used in the United
States for comparative medicine and biomedical research64.
The experimental design was based on 14 young adult male rhesus macaques
divided into three cohorts. Cohort 1 (ZIKVPF-10mo): composed of four animals
(5K6, CB52, 2K2, and 6N1) that were inoculated with 1 × 106 pfu/500 µl of the
ZIKV H/PF/2013 strain subcutaneously16 10 months before DENV-2 challenge.
Cohort 2 (ZIKVPR-2mo): composed of six animals (MA067, MA068, BZ34,
MA141, MA143, and MA085) that were inoculated with 1 × 106 pfu/500 µl of the
ZIKV PRVABC59 strain 2 months before DENV-2 challenge. Both ZIKV strains
used for previous exposure of these groups are > 99.99% comparable in amino acid
identity (Supplementary Table 1). Cohort 3 (naive): composed of four ZIKV/
DENV naive animals (MA123, MA023, MA029, and MA062) as a control group.
Cohorts 1 and 3 were challenged on the same day, while cohort 2 was challenged
3 months later with the same stock of DENV-2. However, all samples were frozen
and analyzed together, except for the immunophenotyping analysis.
The ages of all animals are within the age range for young adults rhesus
macaques https://www.nc3rs.org.uk/macaques/macaques/life-history-and-diet/
(ZIKVPF-10mo: 6.8, 6.8, 5.8, and 5.9; ZIKVPR-2mo: 6.4, 6.5, 5.2, 4.3, 5.6, and 5.5;
naive: 4.8, 6.6, 6.8, and 5.7). Prior to DENV-2 challenge, all animals were subjected
to quarantine period. All cohorts were bled for baseline and challenged
subcutaneously (deltoid area) with 5 × 105 pfu/500 µl of DENV-2 New Guinea
44 strain. After DENV-2 challenge, all animals were extensively monitored by
trained and certified veterinary staff for evidence of disease and clinical status:
external temperature (°C) with an infrared device (EXTECH Instruments,
Waltham, MA, USA), weight (Kg), CBC, and CMP. All animals were bled once
daily from day 1 to day 10 and after that on days 15, 30, 60, and 90 dpi. In all
timepoints, the blood samples were used for serum separation (baseline, 7, 30, 60,
90 dpi only). PBMCs were collected at same timepoints using CPT tubes (BD-
Biosciences, San Jose, CA, USA) containing citrate. Additional heparin samples
were obtained for immunophenotyping by flow cytometry using fresh whole blood.
Figure 1 shows the experimental design and samples collection timeline.
DENV RNAemia. DENV viral RNA extraction was performed from acute serum
samples (baseline, 1–10, and 15 dpi) using a QIAamp Viral RNA mini kit (Qiagen
Inc, Valencia, CA, USA) according to the manufacturer’s instructions. RNAemia
levels were measured by a One-Step qRT-PCR detection kit (Oasig, Primerdesign
Ltd., UK), and using a DENV RT primer/probe Mix kit (Genesig, Primerdesign
Ltd., UK) according to the manufacturer’s protocol (catalog no. oasig-onestep).
Primers are designed to target the 3′ untranslated region (3′ UTR) of all four
DENV serotypes, and have 100% homology with over 95% of reference sequences
contained in the NCBI database. Assays were performed in an iCycler IQ5 Real-
Time Detection System with Optical System Software version 2.1 (Bio-Rad, Her-
cules, CA, USA). Limit of detection (LOD) was 20 copies per milliliter. Further-
more, in order to correlate RNAemia levels with DENV pathogenesis, we
monitored the clinical status for injury and/or clinical manifestations. Complete
blood counts (CBC) were performed for all animals in several timepoints (baseline,
7, and 15 dpi) to determine the absolute number (106 cells/ml) and percent (%) of
lymphocytes (LYM), monocytes (MON), white blood cells (WBC), neutrophils
(NEU), and platelets (PLT). Also, comprehensive metabolic panel (CMP) was
evaluated in several timepoints (baseline, 7, 15, and 30 dpi) to measure con-
centration (U/L) of alkaline phosphatase and liver enzymes alanine amino-
transferase (ALT) and aspartate aminotransferase (AST).
ELISA. Seroreactivity to DENV and cross-reactivity to ZIKV was measured at dif-
ferent timepoints before and after DENV-2 challenge. DENV–IgM (Focus Diag-
nostics, Cypress, CA, USA) was quantified at baseline, 5, 10, 15, and 30 dpi.
DENV–IgG was quantified at baseline, 7, 15, 30, 60, and 90 dpi (Focus Diagnostics,
Cypress, CA, USA). To determine the modulation of serological profile against ZIKV,
we assessed: levels of anti-ZIKV IgM (InBios, Seattle, WA, USA) at baseline, 5, 10, 15
and 30 dpi; anti-ZIKV IgG (XPressBio, Frederick, MD, USA) at baseline, 7, 15, 30, 60,
and 90 dpi; anti-ZIKV NS1-IgG (Alpha Diagnostics, San Antonio, TX, USA) at
baseline, 30, 60, and 90 dpi (including additional timepoints prior baseline for both
ZIKV-immune groups); and anti-ZIKV EDIII–IgG (Alpha Diagnostics International,
San Antonio, TX, USA). All ELISA-based assays were performed following the
manufacturers’ instructions. This serological characterization allows us to assess the
dynamics of DENV and ZIKV cross-reactivity, but without discerning between cross-
reactive binding Abs and cross- or type-specific neutralizing Abs.
Plaque reduction neutralization test. Selected serum samples (baseline, 30, 60,
and 90 dpi) were challenged to neutralized ZIKV (H/PF/2013, PRVABC59),
DENV-1 Western Pacific 74, DENV-2 NGC 44, DENV-3 Sleman 73, and DENV-4
Dominique strains. For the infecting serotype (DENV-2) and ZIKV, the NAbs were
measured in early timepoints as well (7 and 15 dpi). For the PRNT, serum samples
were inactivated, diluted (twofold), mixed with a constant inoculum of virus
(volume necessary to produce ~ 35 pfu/well) and then incubated for 1 h at 37 °C
and 5% CO2. After incubation, virus–serum mix dilutions were added to Vero-81
cells monolayer in flat bottom 24-well plates seeded the day before for 1 h at 37 °C
and 5% CO2, finally overlay medium was added and incubated by several days
(serotype dependent). The results were reported as PRNT60 titers, NAb titer
capable of reduce 60% or more of DENV serotypes or ZIKV strains pfu compared
with the mock (control of virus without serum). A PRNT60 1:20 titer was con-
sidered a positive Neut titer, and < 1:20 as a negative Neut titer. Non-neutralizing
titers < 1:20) were assigned with one-half of the limit of detection for graphs
visualization.
Multiplex cytokine profile. A total of eight cytokines/chemokines were measured
(pg ml−1) by Luminex at baseline, 1, 2, 3, 5, 10, 15, and 30 dpi, including: inter-
feron alpha (IFN-α), interleukin-6 (IL-6), monokine induced by IFN-gamma
(MIG/CXCL9), monocyte chemoattractant protein 1 (MCP-1/CCL2), macrophage
inflammatory protein 1-beta (MIP-1β/CCL4), IL-1 receptor antagonist (IL-1RA),
C–X–C motif chemokine 10 (CXCL10/IP-10), and perforin. The multiplex assay
was conducted as previously described16,65.
Immunophenotyping. Flow cytometry (MACSQuant Analyzer 10, Miltenyi Bio-
tec) analysis was performed to determine the frequency, activation, and pro-
liferation of cell populations of the innate and adaptive immune response based on
the phenotyping strategy of a previous study16 (Supplementary Figs. 7, 8, and 9 for
gating strategy; Supplementary Table 2 for Ab panel). Phenotypic characterization
of macaque PBMCs from fresh whole blood samples was performed by 8-
multicolor flow cytometry using fluorochrome-conjugated Abs at several time-
points (baseline, 1, 2, 3, 7, 10 dpi; and 15 and 30 dpi for B-/T-cell panel only).
Single cells (singlets) were selected by their FSC area (FSC-A) and height (FSC-H)
patterns. Lymphocytes (LYM) were gated based on their characteristic forward and
side scatter pattern (FSC, SSC). T cells were selected gating on the CD3+ popu-
lation. CD4+ and CD8+ T cells were defined as CD3+CD4+ and CD3+CD8+,
respectively. Naive (N; CD28+CD95−), effector memory (EM; CD28−CD95+),
and central memory (CM; CD28+CD95+) T-cell subpopulations were determined
within CD4+ and CD8+ T cells. B cells were defined as CD20+CD3−. The acti-
vation of B- and T-cell memory subpopulations (EM and CM) was assessed by the
presence of the early activation marker CD69. Proliferation of the total and acti-
vated B cells was quantified by the expression of the intracellular marker Ki67.
Natural killer (NK) cells were defined as CD3−CD20−CD14−, and analyzed by the
double-positive expression of the following NK cell markers: CD8, CD56, NKG2A,
NKp30, and NKp46 (Supplementary Fig. 9 for gating strategy). Dendritic cells
(DC) were separated in two populations within the Lineage-DR+ (HLA-DR+
CD3− CD14− CD16− CD20− CD8− NKG2A−) by the expression of CD123
(plasmacytoid, pDC) or CD11c (myeloid, mDCs) (Supplementary Fig. 8 for gating
strategy). Then, DC percentages were calculated from the total PBMCs (total events
of the DC subpopulation divided by total PBMCs and multiplied by 100). The
phenotyping assays were optimized and performed as previously published16,33,66.
T-cell functional response. Intracellular cytokine staining of macaques PBMCs was
performed by multicolor flow cytometry using methods previously described (Sup-
plementary Fig. 14 for gating strategy; Supplementary Table 3 for Ab panel)16,66.
Functional effector response of CD4+ and CD8+ T cells was measured before and
after DENV infection. Antigen-specific CD4+ and CD8+ T-cell effector responses
were measured at baseline to determine basal levels in presence (ZIKVPF-10mo,
ZIKVPR-2mo) or absence (naive) of previous immunity to ZIKV. Also, 30, 60, and 90
dpi were assessed to determine how this pre-existing functional response is modulated
after DENV infection and if is maintained over time. For peptide pools stimulation,
PBMCs were stimulated for 6 h at 37 °C and 5% CO2. The peptides used for DENV-E,
ZIKV-E, and ZIKV–NS were 15-mers overlapped by 10 amino acids at 1.25 µg/ml,
2.5 µg/ml, 475 ng/ml per peptide, respectively (Supplementary Table 4 for peptide
sequences). The stimulation with peptides was performed in presence of brefeldin A
at 10 µg/ml. After stimulation, the cells were stained for the following markers: CD3,
CD4, CD8, CD20 (excluded), CD107a (functional cytotoxicity). Levels of IFN-γ and
TNF-α also were measured in gated lymphocytes cell populations. Samples were
measured, and data were collected on a LSRII (BD).
Statistical analysis. Statistical analyses were performed using GraphPad Prism
7.0 software (GraphPad Software, San Diego, CA, USA). The statistical significance
between the means of all groups were determined using two-way ANOVA multiple
comparison Tukey test, and to compare each mean against the baseline mean
within same group two-way ANOVA multiple comparison Dunnett test was
performed. The total number of families and comparisons per family used for
adjustments are depicted in each figure legend. Significant multiplicity adjusted
p-values (*< 0.05, **< 0.01, ***< 0.001, ****< 0.0001) show statistically significant
difference between groups (Tukey test) or timepoints within a group
(Dunnett test).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are in main Figures and Supplementary Information, any additional
details are available from the authors upon request. The raw data from all main and
supplementary figs. are provided as a Source Data File.
Received: 24 April 2019 Accepted: 3 September 2019
References
1. Metsky, H. C. et al. Zika virus evolution and spread in the Americas. Nature
546, 411–415 (2017).
2. de Oliveira, W. K. et al. Infection-related microcephaly after the 2015 and
2016 Zika virus outbreaks in Brazil: a surveillance-based analysis. Lancet 390,
861–870 (2017).
3. Li, C. et al. Zika virus disrupts neural progenitor development and leads to
microcephaly in mice. Cell Stem Cell 19, 672 (2016).
4. Mlakar, J. et al. Zika virus associated with microcephaly. New Engl. J. Med.
374, 951–958 (2016).
5. Guo, C. et al. Global epidemiology of dengue outbreaks in 1990-2015: a
systematic review and meta-analysis. Front. Cell. Infect. Microbiol. 7, 317
(2017).
6. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496,
504–507 (2013).
7. Katzelnick, L. C. et al. Dengue viruses cluster antigenically but not as discrete
serotypes. Science 349, 1338–1343 (2015).
8. Khurram, M. et al. Dengue hemorrhagic fever: comparison of patients
with primary and secondary infections. J. Infect. Public Health 7, 489–495
(2014).
9. Guzman, M. G. et al. Enhanced severity of secondary dengue-2 infections:
death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Publica 11,
223–227 (2002).
10. Guzman, M. G., Alvarez, M. & Halstead, S. B. Secondary infection as a risk
factor for dengue hemorrhagic fever/dengue shock syndrome: an historical
perspective and role of antibody-dependent enhancement of infection. Arch.
Virol. 158, 1445–1459 (2013).
11. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody
cross-neutralization. Nature 536, 48–53 (2016).
12. Butler, D. Brazil asks whether Zika acts alone to cause birth defects. Nature
535, 475–476 (2016).
13. Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-
dependent enhancement of infection with zika virus. Nat. Immunol.,
https://doi.org/10.1038/ni.3515 (2016).
14. Priyamvada, L. et al. Human antibody responses after dengue virus infection
are highly cross-reactive to Zika virus. Proc. Natl Acad. Sci. USA 113,
7852–7857 (2016).
15. Bardina, S. V. et al. Enhancement of Zika virus pathogenesis by preexisting
antiflavivirus immunity. Science, https://doi.org/10.1126/science.aal4365
(2017).
16. Pantoja, P. et al. Zika virus pathogenesis in rhesus macaques is unaffected by
pre-existing immunity to dengue virus. Nat. Commun. 8, 15674 (2017).
17. McCracken, M. K. et al. Impact of prior flavivirus immunity on Zika virus
infection in rhesus macaques. PLoS Pathog. 13, e1006487 (2017).
18. Terzian, A. C. B. et al. Viral load and cytokine response profile does not
support antibody-dependent enhancement in dengue-primed zika virus-
infected patients. Clin. Infect. Dis. 65, 1260–1265 (2017).
19. Gordon, A. et al. Prior dengue virus infection and risk of Zika: a pediatric
cohort in Nicaragua. PLoS Med. 16, e1002726 (2019).
20. Kam, Y. W. et al. Cross-reactive dengue human monoclonal antibody
prevents severe pathologies and death from Zika virus infections. JCI Insight
2, https://doi.org/10.1172/jci.insight.92428 (2017).
21. Wen, J. et al. Dengue virus-reactive CD8(+) T cells mediate cross-protection
against subsequent Zika virus challenge. Nat. Commun. 8, 1459 (2017).
22. Wen, J. et al. Identification of Zika virus epitopes reveals immunodominant
and protective roles for dengue virus cross-reactive CD8(+) T cells. Nat.
Microbiol. 2, 17036 (2017).
23. Grifoni, A. et al. Prior Dengue virus exposure shapes T cell immunity to Zika
virus in humans. J. Virol., https://doi.org/10.1128/jvi.01469-17 (2017).
24. Perez, F. et al. The decline of dengue in the Americas in 2017: discussion of
multiple hypotheses. Trop. Med. Int. Health, https://doi.org/10.1111/tmi.13200
(2019).
25. Solimini, A. G., Manica, M., Rosa, R., Della Torre, A. & Caputo, B. Estimating
the risk of dengue, chikungunya and Zika outbreaks in a large European city.
Sci. Rep. 8, 16435 (2018).
26. Gutierrez-Lopez, R. et al. Vector competence of Aedes caspius and Ae. albopictus
mosquitoes for Zika virus, Spain. Emerg. Infect. Dis. 25, 346–348 (2019).
27. Ribeiro, G. S. et al. Does immunity after Zika virus infection cross-protect
against dengue? Lancet Glob. Health 6, e140–e141 (2018).
28. Sariol, C. A. & White, L. J. Utility, limitations, and future of non-human
primates for dengue research and vaccine development. Front. Immunol. 5,
452 (2014).
29. Clark, K. B., Onlamoon, N., Hsiao, H. M., Perng, G. C. & Villinger, F. Can
non-human primates serve as models for investigating dengue disease
pathogenesis? Front. Microbiol. 4, 305 (2013).
30. Koraka, P., Benton, S., van Amerongen, G., Stittelaar, K. J. & Osterhaus, A. D.
Characterization of humoral and cellular immune responses in cynomolgus
macaques upon primary and subsequent heterologous infections with dengue
viruses. Microbes Infect. 9, 940–946 (2007).
31. Borges, M. B. et al. Characterization of recent and minimally passaged
Brazilian dengue viruses inducing robust infection in rhesus macaques. PLoS
ONE 13, e0196311 (2018).
32. White, L. J. et al. An alphavirus vector-based tetravalent dengue vaccine
induces a rapid and protective immune response in macaques that differs
qualitatively from immunity induced by live virus infection. J. Virol. 87,
3409–3424 (2013).
33. Sariol, C. A. et al. Decreased dengue replication and an increased anti-viral
humoral response with the use of combined toll-like receptor 3 and 7/8
agonists in macaques. PLoS ONE 6, 9 (2011).
34. Kawiecki, A. B. & Christofferson, R. C. Zika virus-induced antibody response
enhances dengue virus serotype 2 replication in vitro. J. Infect. Dis. 214,
1357–1360 (2016).
35. Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited
by Zika virus infection. Science 353, 823–826 (2016).
36. Fowler, A. M. et al. Maternally acquired Zika antibodies enhance dengue
disease severity in mice. Cell Host Microbe 24, 743–750.e745 (2018).
37. George, J. et al. Prior exposure to Zika virus significantly enhances peak
dengue-2 viremia in Rhesus macaques. Sci. Rep. 7, 10498 (2017).
38. Breitbach, M. E. et al. Primary infection with dengue or Zika virus does not
affect the severity of heterologous secondary infection in macaques. PLoS
Pathog. 15, e1007766 (2019).
39. Anderson, K. B. et al. A shorter time interval between first and second dengue
infections is associated with protection from clinical illness in a school-based
cohort in Thailand. J. Infect. Dis. 209, 360–368 (2014).
40. Montoya, M. et al. Symptomatic versus inapparent outcome in repeat dengue
virus infections is influenced by the time interval between infections and study
year. PLoS Negl. Trop. Dis. 7, e2357 (2013).
41. Kliks, S. C., Nimmanitya, S., Nisalak, A. & Burke, D. S. Evidence that maternal
dengue antibodies are important in the development of dengue hemorrhagic
fever in infants. Am. J. Trop. Med. Hyg. 38, 411–419 (1988).
42. Bhoomiboonchoo, P. et al. Sequential dengue virus infections detected in
active and passive surveillance programs in Thailand, 1994-2010. BMC Public
Health 15, 250 (2015).
43. Arien, K. K., Michiels, J., Foque, N., Heyndrickx, L. & Van Esbroeck, M. Can
Zika virus antibodies cross-protect against dengue virus? Lancet Glob. Health
6, e494 (2018).
44. Ribeiro, G. S. et al. Can Zika virus antibodies cross-protect against dengue
virus?—authors’ reply. Lancet Glob. Health 6, e495 (2018).
45. Katzelnick, L. C. & Harris, E. The use of longitudinal cohorts for studies of
dengue viral pathogenesis and protection. Curr. Opin. Virol. 29, 51–61 (2018).
46. Wahala, W. M. & Silva, A. M. The human antibody response to dengue virus
infection. Viruses 3, 2374–2395 (2011).
47. Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E.
Neutralizing antibody titers against dengue virus correlate with protection
from symptomatic infection in a longitudinal cohort. Proc. Natl Acad. Sci.
USA 113, 728–733 (2016).
48. Weiskopf, D. et al. Dengue virus infection elicits highly polarized CX3CR1+
cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl Acad.
Sci. USA 112, E4256–E4263 (2015).
49. Collins, M. H. et al. Lack of durable cross-neutralizing antibodies against Zika
virus from dengue virus infection. Emerg. Infect. Dis. 23, 773–781 (2017).
50. Dowd, K. A. et al. Broadly neutralizing activity of Zika virus-immune sera
identifies a single viral serotype. Cell Rep. 16, 1485–1491 (2016).
51. Swanstrom, J. A. et al. Dengue virus envelope dimer epitope monoclonal
antibodies isolated from dengue patients are protective against Zika virus.
mBio 7, https://doi.org/10.1128/mBio.01123-01116 (2016).
52. Serrano-Collazo, C. et al. Significant control of Zika infection in macaques
depends on the elapsing time after dengue exposure. bioRxiv, 625293,
https://doi.org/10.1101/625293 (2019).
53. de Alwis, R. et al. In-depth analysis of the antibody response of individuals
exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 5, e1188
(2011).
54. Valiant, W. G. et al. Zika convalescent macaques display delayed induction of
anamnestic cross-neutralizing antibody responses after dengue infection.
Emerg. Microbes Infect. 7, 130 (2018).
55. Montoya, M. et al. longitudinal analysis of antibody cross-neutralization
following Zika virus and dengue virus infection in Asia and the Americas.
J. Infect. Dis. 218, 536–545 (2018).
56. Miller, J. D. et al. Human effector and memory CD8+ T cell responses to
smallpox and yellow fever vaccines. Immunity 28, 710–722 (2008).
57. Knudsen, M. L. et al. Kinetic and phenotypic analysis of CD8+ T cell
responses after priming with alphavirus replicons and homologous or
heterologous booster immunizations. J. Virol. 88, 12438–12451 (2014).
58. Grifoni, A. et al. Cutting edge: transcriptional profiling reveals multifunctional
and cytotoxic antiviral responses of Zika virus-specific CD8(+) T cells. J.
Immunol. 201, 3487–3491 (2018).
59. Gunther, V. J. et al. A human challenge model for dengue infection reveals a
possible protective role for sustained interferon gamma levels during the acute
phase of illness. Vaccine 29, 3895–3904 (2011).
60. Wijeratne, D. T. et al. Quantification of dengue virus specific T cell responses
and correlation with viral load and clinical disease severity in acute dengue
infection. PLoS Negl. Trop. Dis. 12, e0006540 (2018).
61. Elong Ngono, A. et al. CD4+ T cells promote humoral immunity and viral
control during Zika virus infection. PLoS Pathog. 15, e1007474 (2019).
62. Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and
cynomolgus macaques. Nat. Med., https://doi.org/10.1038/nm.4206 (2016).
63. Silveira, E. L. V. et al. Immune cell dynamics in rhesus macaques infected with
a Brazilian strain of Zika virus. J. Immunol. 199, 1003–1011 (2017).
64. Kanthaswamy, S. et al. The population genetic composition of conventional
and SPF colonies of Rhesus Macaques (Macaca mulatta) at the Caribbean
Primate Research Center. J. Am. Assoc. Lab. Anim. Sci. 55, 147–151 (2016).
65. Giavedoni, L. D. Simultaneous detection of multiple cytokines and
chemokines from nonhuman primates using luminex technology. J. Immunol.
Methods 301, 89–101 (2005).
66. Meyer, C., Haberthur, K., Asquith, M. & Messaoudi, I. Flow cytometry-based
methods to characterize immune senescence in nonhuman primates. Methods
Mol. Biol. 1343, 65–80 (2015).
Acknowledgements
We thank all the staff of the Caribbean Primate Research Center and Animal Resources
Center for their continuous support with the sample collection, schedule, and monitoring
of the animals. Authors recognize the support provided by Dr. Elmer Rodriguez
reviewing the statistics. This work was supported by the following grants: 2 P40
OD012217 and 2U42OD021458-15 to C.A.S. and M.I.M., K22AI104794 to J.D.B.,
P51OD011133 (L.G.), HHSN272201400045C to D.W., and R25GM061838 to E.X.P.-G.
Author contributions
C.A.S. and E.X.P.-G. developed the experimental design. I.V.R. and M.I.M. supervised
and performed sample collection and animals monitoring. E.X.P.-G., P.P., C.S.-C.,
M.A.H., A.O.-R., V.H., L.P., L.C., and T.A. performed the experiments. E.X.P.-G., C.A.S.,
V.H., M.A.H., I.V.R., M.I.M., L.J.W., A.d.S., and D.W. analyzed the data. E.X.P.-G. and C.
A.S. drafted the paper. C.A.S., E.X.P.-G., D.W., A.K.P., J.D.B., M.A.H., L.G., L.J.W., and
A.d.S. revised the paper.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-12295-2.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Peer review information Nature Communications thanks Liisa Selin, Koen Van Rompay
and the other, anonymous, reviewer(s) for their contribution to the peer review of this
work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
